GlassScriptPhysician profile
Jacob Tyler Shreve
NPI 1497242713
$3,771.87
in general payments reported to CMS, 2019-2025
42 companies · $3,143 in 2025
The $3,143 reported for 2025 was more than what 75% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $629 · 2025: $3,143.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,485 · Education: $287.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,485.19 |
| Education | $286.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $448.93 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $428.87 | 2024-2025 | Imfinzi, Enhertu, Lynparza |
| Janssen Biotech, INC. | $205.21 | 2024-2025 | Erleada, Darzalex |
| Abbvie INC. | $183.44 | 2024-2025 | |
| E.R. Squibb & Sons, L.L.C. | $177.08 | 2024-2025 | Opdivo |
| Alexion Pharmaceuticals, INC. | $176.83 | 2024-2025 | Ultomiris, Strensiq |
| Merck Sharp & Dohme LLC | $172.54 | 2024-2025 | Keytruda, Welireg, Lynparza |
| Daiichi Sankyo INC. | $161.84 | 2024-2025 | Enhertu, Vanflyta |
| Incyte Corporation | $150.67 | 2024-2025 | Monjuvi, Jakafi, Pemazyre |
| Beone Medicines USA, INC. | $148.90 | 2025 | Brukinsa, Tevimbra |
| Astellas Pharma US INC | $142.30 | 2025 | Xtandi, Padcev |
| Genentech USA, INC. | $139.93 | 2025 | Tecentriq, Venclexta, Gazyva |
| Pfizer INC. | $105.44 | 2024-2025 | |
| Caris Mpi, INC. | $94.45 | 2025 | Mi Cancer Seek |
| Pharmacosmos Therapeutics INC. | $86.46 | 2025 | Monoferric |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jacob Shreve listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.